Heart-Thickening drug trial aims to reverse damage

NCT ID NCT07655362

Not yet recruiting Disease control Sponsor: Subodh Verma Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 3 trial tests whether adding baxdrostat (Baxfendy) to standard care can improve heart structure and function in 286 adults with high blood pressure and thickened heart walls. Participants take either baxdrostat or a placebo daily for 12 months, with heart scans and regular checkups to measure changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: baxdrostat (Baxfendy)
What this could lead to: If successful, baxdrostat could become a new add-on treatment to help reverse heart thickening and improve heart function in people with high blood pressure.
What could go wrong: This is a Phase 3 trial, but results are not yet known. The drug may not improve heart structure more than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC REMODELING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertensive disorder Ventricular Remodeling

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC REMODELING

Contacts and locations

Locations

Diagnostic Assessment Centre

Toronto, Ontario, M1S4N6, Canada
North York Diagnostic and Cardiac Centre

North York, Ontario, M6B3H7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.